Shanghai Bio-Heart Biological Technology Co., Ltd. engages in the research and development of interventional cardiovascular device therapies. The company is headquartered in Shanghai, Shanghai and currently employs 70 full-time employees. The company went IPO on 2021-12-23. The firm's main businesses are the development and production of interventional cardiovascular devices. The firm's main products comprise fully bioresorbable scaffolds (BRS) and renal denervation (RDN). The firm's products are mainly used to meet medical needs for the treatment of coronary, peripheral artery disease and hypertension. The firm's products are used in addressing the unmet medical needs of Chinese patients for the treatment of coronary artery diseases and the unmet medical needs of patients for the treatment of uncontrolled hypertension. The firm mainly conducts its businesses in the domestic market and overseas markets.
02185.HK stock price ended at $6.06 on 星期二, after dropping 2.10%
On the latest trading day Jan 20, 2026, the stock price of 02185.HK fell by 2.10%, dropping from $6.16 to $6.06. During the session, the stock saw a volatility of 3.70%, with prices oscillating between a daily low of $5.94 and a high of $6.16. On the latest trading day, the trading volume for 02185.HK decreased by 149.9K shares, aligning with the declining prices, which may indicate weakening market confidence in the near term. In total, 61.6K shares were traded, with a market value of approximately $1.4B.